Enhanced Outcomes in Type 2 Diabetes Patients With Acute Kidney Disease Through Thiazolidinedione
Authors' conclusion
TZD demonstrated a notable reduction in mortality, cardiovascular events, and kidney-related adverse events among T2DM patients with AKD. These findings suggest a potential benefit of TZD usage for managing cardiovascular events in T2DM patients with AKD.
Study context
- Population
- Patients with T2D and acute kidney disease (AKD), TriNetX platform before September 30, 2022; Thiazolidinedione (TZD) users after propensity score matching (PSM): 53.82% male, mean age 64.0 ± 13.5 yearsPSM 1:1
- Participants
- 263,101 patients
- Exposure
- TZD use during AKD vs no TZD use
- TZDn = 2,555
- Outcome
- All-cause mortality, major adverse cardiovascular events (MACE) and major adverse kidney events (MAKE)
- Follow-up
- Median 1.5 years
Methodological details1:1 propensity score matching, TriNetX platform
- 1:1 propensity score matching
- TriNetX platform
Main finding
As reported in the abstract
Each group vs non-usersEstimate (95% CI)
TZD
HR (all-cause mortality) 0.68(0.57–0.81)
TZD
HR (MACE) 0.68(0.58–0.80)
TZD
HR (MAKE) 0.75(0.66–0.86)
Observational data: associations, not effects.
Further findings
- TZD use during AKD period
- 1.03% · 2723
Original publication
Enhanced Outcomes in Type 2 Diabetes Patients With Acute Kidney Disease Through Thiazolidinedione. J Clin Endocrinol Metab. Published 13 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →